{"product_id":"venlafaxine-why-this-common-antidepressant-may-be-riskier-than-most-ssris","title":"Venlafaxine: Why This Common Antidepressant May Be Riskier Than Most SSRIs","description":"\u003cp\u003eThis review of published research warns that venlafaxine, a commonly prescribed antidepressant, carries more serious risks than most selective serotonin reuptake inhibitor (SSRI) antidepressants, including a higher chance of fatal overdose and cardiovascular side effects. While venlafaxine works similarly to SSRIs for treating depression, it offers no proven advantage in effectiveness, making it a less attractive treatment option for most patients. The evidence reviewed as of mid-2015 consistently points to dose-dependent blood pressure elevation, heart rhythm problems, and pregnancy complications. For most patients, an SSRI other than citalopram or escitalopram represents a safer choice.\u003c\/p\u003e\n\n\u003ch1\u003eVenlafaxine: Why This Common Antidepressant May Be Riskier Than Most SSRIs\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eUnderstanding Venlafaxine and How It Works\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#why-matters\"\u003eWhy This Research Matters to Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Review Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#findings\"\u003eKey Findings: The Evidence in Detail\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations: What the Evidence Couldn't Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients and Doctors\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eVenlafaxine has a higher risk of fatal overdose and cardiovascular side effects than most SSRIs.\u003c\/li\u003e\n\u003cli\u003eVenlafaxine offers no proven advantage in effectiveness over SSRIs for treating depression.\u003c\/li\u003e\n\u003cli\u003eVenlafaxine can cause dose-dependent blood pressure elevation and QT prolongation, a heart rhythm abnormality.\u003c\/li\u003e\n\u003cli\u003eTaking venlafaxine in the second and third trimesters of pregnancy increases risk of pre-eclampsia and eclampsia.\u003c\/li\u003e\n\u003cli\u003eFor most patients, an SSRI other than citalopram or escitalopram is a safer choice than venlafaxine.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eUnderstanding Venlafaxine and How It Works\u003c\/h2\u003e\n\n\u003cp\u003eVenlafaxine (brand name Effexor and others) is an antidepressant that belongs to a class of medications known as \u003cstrong\u003eserotonin and norepinephrine reuptake inhibitors (SNRIs)\u003c\/strong\u003e. It works by blocking the reuptake of two brain chemicals—serotonin and norepinephrine—both of which play important roles in regulating mood, energy, and stress responses.\u003c\/p\u003e\n\n\u003cp\u003eIn contrast, \u003cstrong\u003eselective serotonin reuptake inhibitors (SSRIs)\u003c\/strong\u003e, such as fluoxetine (Prozac), sertraline (Zoloft), and paroxetine (Paxil), affect only serotonin. This difference in mechanism is central to why venlafaxine has a distinct safety profile.\u003c\/p\u003e\n\n\u003cp\u003eBecause venlafaxine also increases norepinephrine activity, it triggers what the review calls \u003cstrong\u003enoradrenergic adverse effects\u003c\/strong\u003e—side effects related to the body's noradrenaline (norepinephrine) system. The most significant of these involve the cardiovascular system.\u003c\/p\u003e\n\n\u003cp\u003eThe review notes that venlafaxine reproduces all the serotonergic side effects seen with SSRIs—such as nausea, sexual dysfunction, and gastrointestinal disturbances—while \u003cstrong\u003eadditionally\u003c\/strong\u003e introducing cardiovascular risks that SSRIs generally do not carry. This combination of overlapping and extra risks is the cornerstone of the safety concern.\u003c\/p\u003e\n\n\u003cp\u003eIt is also important to note what the review found regarding effectiveness: venlafaxine offers \u003cstrong\u003eno demonstrated advantages over SSRIs in terms of efficacy\u003c\/strong\u003e. Both drug classes produce similar results in treating depression, meaning patients get the same potential benefit with venlafaxine but at a higher cost in terms of side effects and risks.\u003c\/p\u003e\n\n\u003ch2 id=\"why-matters\"\u003eWhy This Research Matters to Patients\u003c\/h2\u003e\n\n\u003cp\u003eDepression affects hundreds of millions of people worldwide, and antidepressants are among the most frequently prescribed medications. When a patient is diagnosed with depression, the choice of antidepressant can shape their daily life for months or years. Side effects influence whether patients stay on their medication, and some side effects—particularly heart-related ones—can be dangerous.\u003c\/p\u003e\n\n\u003cp\u003eThis review matters because it synthesizes multiple lines of evidence—clinical trials, overdose databases, pregnancy registries, and large national health records—to give a comprehensive picture of venlafaxine's harms. The conclusion is clear and actionable: for most patients, the risk-benefit balance favors SSRIs over venlafaxine.\u003c\/p\u003e\n\n\u003cp\u003eUnderstanding these risks is especially important for patients currently taking venlafaxine or those considering it. The findings do not suggest that everyone on venlafaxine is in immediate danger, but they do indicate that doctors and patients should carefully weigh whether continued use is justified.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Review Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThis is a \u003cstrong\u003enarrative review article\u003c\/strong\u003e published in \u003cem\u003ePrescrire International\u003c\/em\u003e, a peer-reviewed journal known for rigorous, independent assessments of medications. The review drew on multiple sources of evidence available as of mid-2015:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCohort studies\u003c\/strong\u003e using a UK primary care database that tracked overdose outcomes in patients taking venlafaxine versus SSRIs\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMeta-analyses\u003c\/strong\u003e of more than 70 published and unpublished randomized clinical trials, including about 7,000 patients in total\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEpidemiological studies\u003c\/strong\u003e examining pregnancy outcomes in women exposed to venlafaxine\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eObservational studies\u003c\/strong\u003e of elderly patients and reported suicide attempts involving venlafaxine overdose\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLarge national cohort studies\u003c\/strong\u003e from Britain and Denmark investigating sudden cardiac death\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBy combining clinical trial data with real-world epidemiological evidence, the review aimed to capture both the controlled-experiment view of side effects and the messier reality of how the drug performs in everyday use, including in overdose situations.\u003c\/p\u003e\n\n\u003cp\u003eThe review did not perform new statistical analyses of its own. Instead, it carefully aggregated and weighed existing studies to identify consistent patterns and to evaluate the strength and limitations of each source of evidence.\u003c\/p\u003e\n\n\u003ch2 id=\"findings\"\u003eKey Findings: The Evidence in Detail\u003c\/h2\u003e\n\n\u003ch3\u003eFatal Overdoses Are More Common With Venlafaxine\u003c\/h3\u003e\n\n\u003cp\u003eSeveral cohort studies using data from a UK database found a disturbing pattern: \u003cstrong\u003evenlafaxine overdoses are more frequently fatal than SSRI overdoses\u003c\/strong\u003e. In practical terms, a patient who takes too much venlafaxine is more likely to die from the overdose than a patient who takes too much of an SSRI. This difference is thought to relate to venlafaxine's effects on the heart and blood vessels, which can be overwhelming in overdose.\u003c\/p\u003e\n\n\u003ch3\u003eHigher Rates of Treatment Discontinuation Due to Side Effects\u003c\/h3\u003e\n\n\u003cp\u003eMeta-analyses pooling results from more than 70 randomized clinical trials—including studies that were never published, which helps reduce publication bias—showed that \u003cstrong\u003etreatment discontinuation due to adverse effects is more common with venlafaxine than with SSRI antidepressants\u003c\/strong\u003e. These trials included about 7,000 patients in total, giving the finding substantial statistical weight.\u003c\/p\u003e\n\n\u003cp\u003eStopping a medication because of side effects is clinically meaningful. It means patients are suffering through uncomfortable or dangerous effects, and it often leads to switching drugs or abandoning treatment altogether, which can leave depression untreated.\u003c\/p\u003e\n\n\u003ch3\u003eDose-Dependent Blood Pressure Elevation\u003c\/h3\u003e\n\n\u003cp\u003eVenlafaxine can provoke \u003cstrong\u003edose-dependent blood pressure elevation\u003c\/strong\u003e. This means that as the dose goes up, so does blood pressure, sometimes to levels that require the medication to be stopped. For patients with existing hypertension or heart disease, this effect is especially concerning.\u003c\/p\u003e\n\n\u003cp\u003eBlood pressure elevation is a direct consequence of venlafaxine's noradrenergic action: norepinephrine constricts blood vessels and increases cardiac output, raising pressure within the arteries. Prolonged elevation can damage the heart, kidneys, eyes, and brain.\u003c\/p\u003e\n\n\u003ch3\u003ePregnancy Risks: Pre-Eclampsia and Eclampsia\u003c\/h3\u003e\n\n\u003cp\u003eExposure to venlafaxine during the \u003cstrong\u003esecond and third trimesters of pregnancy increases the risk of pre-eclampsia and eclampsia\u003c\/strong\u003e. Pre-eclampsia is a serious condition characterized by high blood pressure and signs of organ damage, usually affecting the kidneys and liver, during pregnancy. Eclampsia is a more severe, life-threatening progression that can cause seizures and coma.\u003c\/p\u003e\n\n\u003cp\u003eThese risks are particularly noteworthy because pregnancy itself already places strain on the cardiovascular system, and venlafaxine's blood pressure effects compound that strain. For pregnant women with depression, the choice of antidepressant therefore requires careful consideration of fetal and maternal safety.\u003c\/p\u003e\n\n\u003ch3\u003eHeart Rhythm Abnormalities: QT Prolongation and Torsades de Pointes\u003c\/h3\u003e\n\n\u003cp\u003eA cohort study involving about \u003cstrong\u003e50 elderly patients\u003c\/strong\u003e and analysis of \u003cstrong\u003eseveral hundred reported suicide attempts by venlafaxine overdose\u003c\/strong\u003e demonstrated a risk of \u003cstrong\u003eQT interval prolongation\u003c\/strong\u003e. The QT interval is a measure of the electrical activity of the heart on an electrocardiogram (ECG); when it becomes abnormally long, the heart's electrical system becomes unstable.\u003c\/p\u003e\n\n\u003cp\u003eQT prolongation can lead to \u003cstrong\u003etorsades de pointes\u003c\/strong\u003e, an unusual and potentially fatal type of ventricular tachycardia (a rapid, abnormal heart rhythm originating in the lower chambers of the heart). Torsades de pointes may degenerate into ventricular fibrillation, which is immediately life-threatening.\u003c\/p\u003e\n\n\u003cp\u003eThis finding means that venlafaxine in overdose—and possibly at therapeutic doses in vulnerable individuals such as the elderly—can set the stage for catastrophic heart rhythm disturbances. Patients with pre-existing heart conditions or those taking other medications that prolong the QT interval may face even higher risks.\u003c\/p\u003e\n\n\u003ch3\u003eSudden Cardiac Death: A Nuanced Picture\u003c\/h3\u003e\n\n\u003cp\u003eLarge British and Danish cohort studies found \u003cstrong\u003eno increased risk of sudden cardiac death with venlafaxine compared with other antidepressants\u003c\/strong\u003e. This might sound like reassuring news, and in one sense it is: at a population level, venlafaxine did not stand out as causing more sudden deaths than its alternatives.\u003c\/p\u003e\n\n\u003cp\u003eHowever, this finding must be interpreted with caution, as discussed below in the limitations section.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe overall picture assembled by this review is consistent with what doctors know about venlafaxine's pharmacology. Because venlafaxine works on both serotonin and norepinephrine, it inherits the serotonergic side effects of SSRIs and adds a layer of noradrenergic cardiovascular risks. None of this would be especially problematic if venlafaxine were dramatically more effective than SSRIs—but it is not.\u003c\/p\u003e\n\n\u003cp\u003eThe key takeaway is that \u003cstrong\u003evenlafaxine has a higher risk of cardiovascular adverse effects and fatal overdoses than most SSRI antidepressants, with no compensatory benefit in treating depression\u003c\/strong\u003e. When two treatments offer the same chance of improvement but one carries more serious risks, the safer option is generally preferable.\u003c\/p\u003e\n\n\u003cp\u003eFor patients considering antidepressant therapy, this means that SSRIs are a \u003cstrong\u003emore reasonable first-line option\u003c\/strong\u003e in most cases. The exception noted in the review involves two specific SSRIs, citalopram (Celexa) and its close relative escitalopram (Lexapro), which also expose patients to more cardiovascular adverse effects than other SSRIs, including QT prolongation. For those two drugs, the same risk-benefit logic that argues against venlafaxine applies with some force.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations: What the Evidence Couldn't Prove\u003c\/h2\u003e\n\n\u003cp\u003eThe review is honest about the limits of the available evidence, and patients should be aware of these caveats.\u003c\/p\u003e\n\n\u003cp\u003eRegarding sudden cardiac death, the large British and Danish cohort studies that found no increased risk enrolled relatively few venlafaxine users: only \u003cstrong\u003e3.5% and 7% of the patients in those studies\u003c\/strong\u003e were actually taking venlafaxine. This means the studies had \u003cstrong\u003erelatively low statistical power\u003c\/strong\u003e to detect a true difference if one existed.\u003c\/p\u003e\n\n\u003cp\u003eA study with low statistical power can fail to detect a real effect, producing a \"no difference\" result that is really an \"unable to detect a difference\" result. In plain language: the absence of evidence of increased sudden cardiac death is not the same as evidence of absence.\u003c\/p\u003e\n\n\u003cp\u003eThe review also notes that its conclusions rest on data available as of mid-2015. Since then, additional research may have emerged that could refine or change these conclusions, although no major paradigm shift is indicated by the included studies.\u003c\/p\u003e\n\n\u003cp\u003eAnother caveat is that the elderly cohort study of QT prolongation was small (about 50 patients). While the suicide attempt data added weight, the sample sizes in this area are not large enough to precisely quantify the risk of torsades de pointes in everyday therapeutic use as opposed to overdose.\u003c\/p\u003e\n\n\u003cp\u003eFinally, the review is based on aggregate evidence rather than individual patient data, which limits the ability to explore how risk varies with patient characteristics like age, sex, genetic differences in drug metabolism, or coexisting medical conditions.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients and Doctors\u003c\/h2\u003e\n\n\u003cp\u003eMost patients will come to this information in one of two situations: they are prescribed venlafaxine and want to understand it, or they are currently taking it and wondering whether to continue. Here is practical guidance based on the review:\u003c\/p\u003e\n\n\u003ch3\u003eFor Patients Considering a New Antidepressant\u003c\/h3\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss SSRIs first.\u003c\/strong\u003e For most patients with depression, an SSRI offers a better balance of benefit and risk than venlafaxine. Ask your doctor specifically about fluoxetine, sertraline, paroxetine, or similar agents.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBe cautious with citalopram and escitalopram.\u003c\/strong\u003e If cardiovascular risks are a personal concern, note that these two SSRIs also carry more cardiovascular adverse effects than other SSRIs. Mention any personal or family history of heart problems to your doctor.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about your heart.\u003c\/strong\u003e If your doctor recommends venlafaxine for any reason, ask whether an ECG to check your QT interval would be appropriate, especially if you are older or take other medications.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your blood pressure baseline.\u003c\/strong\u003e Venlafaxine can raise blood pressure in a dose-dependent way. If you take it, regular blood pressure monitoring is essential.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch3\u003eFor Patients Currently Taking Venlafaxine\u003c\/h3\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDo not stop abruptly.\u003c\/strong\u003e Stopping venlafaxine suddenly can cause severe withdrawal symptoms, including dizziness, nausea, headache, and electrical shock-like sensations. Any change should be planned with your doctor.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHave an honest conversation.\u003c\/strong\u003e Ask your doctor whether the reasons for prescribing venlafaxine are still valid, and whether an SSRI switch is worth considering. The evidence suggests most patients would do equally well on an SSRI with fewer risks.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMonitor for warning signs.\u003c\/strong\u003e If you experience palpitations, fainting, seizures, severe headache, or significantly elevated home blood pressure readings, seek medical attention promptly.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf pregnant or planning pregnancy, talk to your obstetric provider.\u003c\/strong\u003e The increased risk of pre-eclampsia and eclampsia during the second and third trimesters warrants careful monitoring of blood pressure and close prenatal follow-up.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSafe storage matters.\u003c\/strong\u003e Because venlafaxine overdoses are more frequently fatal than SSRI overdoses, secure storage of the medication—and limiting the quantity dispensed—is a reasonable precaution, particularly for patients with suicidal thoughts.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch3\u003eFor Doctors and Prescribers\u003c\/h3\u003e\n\u003cp\u003eThe review is unambiguous in its conclusion: \u003cstrong\u003evenlafaxine is best avoided in most circumstances\u003c\/strong\u003e. Because venlafaxine and SSRIs have similar and limited efficacy, and because venlafaxine carries greater cardiovascular risk and overdose lethality, an SSRI is a more reasonable option for most patients. Prescribing venlafaxine should be reserved for situations where SSRIs have failed, are contraindicated, or where there is some specific reason to expect an advantage—and even then, with careful cardiovascular monitoring.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eIs venlafaxine riskier than other antidepressants?\u003c\/h3\u003e\n\u003cp\u003eYes, a review of published research found venlafaxine has a higher risk of fatal overdose and cardiovascular side effects than most SSRIs. It also causes more side-effect-related treatment discontinuation. Venlafaxine offers no proven advantage in effectiveness over SSRIs, so for most patients, an SSRI other than citalopram or escitalopram is a safer choice.\u003c\/p\u003e\n\u003ch3\u003eHow does venlafaxine cause heart problems?\u003c\/h3\u003e\n\u003cp\u003eVenlafaxine can cause dose-dependent blood pressure elevation and heart rhythm abnormalities called QT prolongation, which can lead to a dangerous rhythm called torsades de pointes. These risks come from its effect on norepinephrine. In one study of about 50 elderly patients and several hundred overdose cases, QT prolongation was observed.\u003c\/p\u003e\n\u003ch3\u003eCan venlafaxine overdose be fatal?\u003c\/h3\u003e\n\u003cp\u003eYes. Cohort studies using a UK primary care database found venlafaxine overdoses are more frequently fatal than SSRI overdoses. This is likely due to its effects on the heart and blood vessels, which can be overwhelming in overdose. Safe storage and limiting the quantity dispensed are reasonable precautions, especially for patients with suicidal thoughts.\u003c\/p\u003e\n\u003ch3\u003eWhat are the risks of taking venlafaxine during pregnancy?\u003c\/h3\u003e\n\u003cp\u003eExposure to venlafaxine during the second and third trimesters of pregnancy increases the risk of pre-eclampsia and eclampsia, serious conditions involving high blood pressure and organ damage. Eclampsia can cause seizures and coma. If you are pregnant or planning pregnancy, talk to your obstetric provider about careful blood pressure monitoring and prenatal follow-up.\u003c\/p\u003e\n\u003ch3\u003eShould I stop taking venlafaxine if I’m worried about these risks?\u003c\/h3\u003e\n\u003cp\u003eDo not stop abruptly. Stopping suddenly can cause severe withdrawal symptoms, including dizziness, nausea, headache, and electric shock-like sensations. Have an honest conversation with your doctor about whether continued use is justified and whether switching to an SSRI might be appropriate. The evidence suggests most patients would do equally well on an SSRI with fewer risks.\u003c\/p\u003e\n\u003ch3\u003eIf I take venlafaxine, what should I monitor?\u003c\/h3\u003e\n\u003cp\u003eMonitor your blood pressure regularly because venlafaxine can raise it in a dose-dependent way. Seek medical attention promptly if you experience palpitations, fainting, seizures, severe headache, or significantly elevated home blood pressure readings. If you are older or take other medications, ask your doctor whether an ECG to check your QT interval would be appropriate.\u003c\/p\u003e\n\u003ch3\u003eIs venlafaxine more effective than SSRIs for depression?\u003c\/h3\u003e\n\u003cp\u003eNo. The review found venlafaxine offers no demonstrated advantages over SSRIs in terms of efficacy. Both drug classes produce similar results in treating depression. This means patients get the same potential benefit with venlafaxine but at a higher cost in terms of side effects and risks, making SSRIs a more reasonable first-line option for most patients.\u003c\/p\u003e\n\u003ch3\u003eShould I get a second opinion before starting venlafaxine for depression?\u003c\/h3\u003e\n\u003cp\u003eYes, a second opinion can help you weigh the risks. Venlafaxine has a higher risk of fatal overdose and cardiovascular side effects than most SSRIs, with no proven advantage in effectiveness. For most patients, an SSRI other than citalopram or escitalopram is a safer choice. If your doctor recommends venlafaxine, a second opinion can confirm whether it is truly necessary or if a safer alternative exists. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Venlafaxine  more dangerous than most  selective  serotonergic antidepressants - PubMed\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e \u003cem\u003ePrescrire International\u003c\/em\u003e, April 2016, volume 25, issue 170, pages 96–99\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePMID:\u003c\/strong\u003e 27186622\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e No individual authors listed (review produced by the Prescrire editorial team)\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication type:\u003c\/strong\u003e Peer-reviewed review article\u003c\/p\u003e\n\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research published in the National Library of Medicine's PubMed database. It explains and contextualizes the original review for a general audience but does not replace professional medical advice. Always consult a qualified healthcare provider regarding any questions about antidepressant medications, dosing changes, or treatment decisions.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47459136372892,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.sg\/products\/venlafaxine-why-this-common-antidepressant-may-be-riskier-than-most-ssris","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}